| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥8.1B | ¥5.1B | +42.8% |
| Operating Income | ¥-2.8B | ¥-2.3B | -24.7% |
| Ordinary Income | ¥-2.6B | ¥-2.2B | -16.1% |
| Net Income | ¥-4.2B | ¥-2.2B | -86.1% |
| ROE | -13833.3% | -54.4% | - |
FY2025 quarterly results showed revenue of 8.1B yen (YoY +42.8%), representing robust top-line growth, while profitability deteriorated significantly. Operating loss expanded to -2.8B yen from -2.3B yen in the prior year period (YoY -24.7% worsening), ordinary loss reached -2.6B yen (YoY -16.1% worsening), and net loss deepened to -4.2B yen from -2.2B yen (YoY -86.1% worsening). The sharp deterioration in net income was driven by a non-recurring impairment loss of 1.6B yen. Gross profit grew to 2.3B yen with a margin of 28.7%, but SG&A expenses of 5.1B yen consumed 63.9% of revenue, overwhelming the top-line gains. Total assets declined to 4.4B yen from 6.6B yen as total equity was nearly depleted to 0.0B yen from 4.1B yen, reflecting severe balance sheet erosion from accumulated losses. Operating cash flow remained negative at -1.2B yen though improving 33.0% YoY, while free cash flow registered -1.8B yen. The company maintains full-year guidance of 11.5B yen revenue (YoY +42.8%), 0.5B yen operating income, and 0.4B yen net income, projecting a return to profitability.
Revenue growth of +42.8% to 8.1B yen demonstrates strong demand expansion, with gross profit increasing to 2.3B yen at a 28.7% margin, up from 1.7B yen in the prior year. The improvement in absolute gross profit indicates successful revenue scaling despite unchanged margin percentage. However, SG&A expenses surged to 5.1B yen (63.9% of revenue) from 4.0B yen (78.5% of prior year revenue), growing at a rate that exceeded revenue growth. This disproportionate cost increase drove operating loss expansion to -2.8B yen from -2.3B yen, reflecting operating leverage working in reverse. Non-operating items contributed a net positive 0.3B yen, comprising primarily other non-operating income, moderating the ordinary loss to -2.6B yen. The gap between ordinary income (-2.6B yen) and net income (-4.2B yen) of approximately 1.6B yen stems from extraordinary losses, specifically impairment losses of 1.6B yen recognized during the period. This non-recurring factor represents a significant one-time charge that accounts for the 86.1% YoY deterioration in net income beyond operational factors. The earnings pattern represents revenue up/profit down, where strong top-line growth could not offset accelerating fixed cost burdens and was further impaired by asset write-downs.
[Profitability] Operating margin was -35.2%, deteriorating substantially from operational losses as SG&A ratio exceeded gross margin. ROE registered -13,833.3%, an extreme negative figure driven by net loss of -4.2B yen against near-zero equity base of 0.0B yen. The severe ROE distortion reflects accumulated deficit expansion in retained earnings to -9.0B yen from -4.8B yen, causing equity capital erosion. Net profit margin was -51.5%, indicating that losses exceeded half of revenue generation. [Cash Quality] Cash and deposits stood at 1.0B yen, covering only 0.32 times short-term borrowings of 3.3B yen, revealing inadequate liquidity buffer. Operating cash flow to net income ratio was 0.29, suggesting limited cash conversion from reported earnings. [Investment Efficiency] Total asset turnover reached 1.85 times, indicating relatively efficient asset utilization for revenue generation despite profitability challenges. Intangible assets totaled 1.2B yen including goodwill of 0.5B yen, representing substantial non-physical asset concentration. [Financial Health] Equity ratio deteriorated to 0.7% from prior levels, reflecting near-complete equity depletion. Current ratio registered 95.1%, falling below the 100% safety threshold as current assets of 4.1B yen covered only 95% of current liabilities of 4.3B yen. Debt-to-equity ratio reached 144.6 times due to interest-bearing debt of 3.3B yen against minimal equity base. Short-term debt ratio was 98.0%, indicating acute maturity concentration risk with 3.3B yen of the 3.3B yen total debt maturing within one year.
Operating cash flow of -1.2B yen improved 33.0% from the prior year's -1.8B yen, though remaining in deficit territory as operational losses continued to consume cash. The operating CF represented 0.29 times net income, indicating that cash outflows were proportionally smaller than accounting losses. Investing cash flow registered -0.6B yen, driven primarily by intangible asset acquisitions rather than tangible capex, with capital expenditure of only 0.1B yen against depreciation and amortization of 0.3B yen. Working capital changes showed a 0.8B yen decrease in receivables contributing positively to cash flow, while inventory increased by 0.1B yen and payables rose by 0.2B yen, reflecting modest working capital support. Free cash flow totaled -1.8B yen, combining negative operating and investing flows. Financing cash flow provided a positive 1.8B yen inflow, offsetting operational and investment cash consumption. The cash and deposits balance of 1.0B yen against short-term borrowings of 3.3B yen yields coverage of 0.32 times, warranting close monitoring of refinancing capacity and liquidity risk.
Ordinary income of -2.6B yen compared to operating income of -2.8B yen shows net non-operating contribution of approximately 0.3B yen, representing 3.2% of revenue. The non-operating segment provided modest support through other non-operating income, partially offsetting operational losses. Extraordinary losses of 1.6B yen, entirely composed of impairment charges, created a substantial gap between ordinary income and net income, expanding the net loss by approximately 60%. This impairment represents a non-recurring reduction in asset carrying values, likely related to goodwill or intangible assets given the balance sheet composition. Operating cash flow of -1.2B yen exceeded net income of -4.2B yen in absolute terms, suggesting that non-cash charges including the 1.6B yen impairment and 0.3B yen depreciation/amortization contributed significantly to accounting losses while cash outflows were more moderate. The accrual ratio calculated as (Net Income - Operating CF) / Total Assets approximates -67.2%, indicating large divergence between accrual earnings and cash generation, though this is heavily influenced by the one-time impairment. Excluding the extraordinary impairment, core earnings quality shows persistent cash consumption from operations that aligns with ongoing operating losses.
Full-year guidance projects revenue of 11.5B yen, operating income of 0.5B yen, ordinary income of 0.5B yen, and net income of 0.4B yen. Current quarter results represent 70.1% progress on revenue against the annual target, indicating strong first-half execution. However, operating income progress is negative given cumulative losses to date versus the 0.5B yen full-year target, requiring a significant turnaround in remaining periods to achieve profitability. The implied second-half performance requires operating income of approximately 3.3B yen from remaining 3.4B yen revenue to reach targets, suggesting expectations for substantial margin improvement. At current quarter run-rates, the 0.5B yen operating income target implies an operating margin recovery from -35.2% to approximately +4.3% for the full year, representing a material inflection. Key assumptions embedded in guidance likely include SG&A cost stabilization or reduction, absence of additional impairments, and continued revenue momentum at similar growth rates. The guidance revision status is not specified, suggesting initial targets remain unchanged despite first-half losses.
Liquidity and refinancing risk represents the most immediate concern, as short-term borrowings of 3.3B yen increased 124.9% from 1.5B yen in the prior period while cash coverage deteriorated to 0.32 times. The 95.1% current ratio and 98.0% short-term debt concentration create vulnerability to funding disruptions or covenant breaches requiring immediate management attention. Equity capital erosion from accumulated losses totaling -9.0B yen has reduced the equity base to 0.0B yen with an equity ratio of 0.7%, leaving minimal buffer to absorb further losses and potentially triggering debt covenants or restricting access to additional credit facilities. Asset impairment recurrence risk stems from goodwill of 0.5B yen and total intangible assets of 1.2B yen representing substantial value relative to the depleted equity base, where further impairments would directly threaten solvency given the absence of equity cushion to absorb write-downs.
[Industry Position] (Reference - Proprietary Analysis) Industry benchmark data was not provided in the source materials for comparative analysis. The company operates with an equity ratio of 0.7%, operating margin of -35.2%, and ROE of -13,833.3%, indicating severe financial distress relative to typical corporate health standards. Current ratio of 95.1% falls below the standard liquidity threshold of 100-200%, while debt-to-equity of 144.6 times vastly exceeds conventional leverage norms. These metrics position the company in financial rehabilitation territory requiring urgent capital restructuring measures to restore viability.
Revenue growth momentum of 42.8% demonstrates market acceptance and demand expansion for the company's offerings, with gross profit scaling proportionally and indicating viable product economics at the gross margin level. The structural challenge lies in the fixed cost base, where SG&A expenses of 5.1B yen consume 63.9% of revenue, requiring either revenue scale to reach breakeven threshold estimated above 12-13B yen annually at current cost structure, or material cost rationalization to achieve profitability at lower revenue levels. The balance sheet deterioration to near-zero equity with 1.6B yen non-recurring impairment charges highlights asset base vulnerability, particularly the 1.2B yen intangible asset concentration including goodwill, which may face additional impairment pressure if turnaround efforts falter. Management's full-year guidance projecting return to 0.5B yen operating profit and 0.4B yen net income implies expectation of significant margin inflection in subsequent quarters, though execution risk is elevated given the -1.8B yen free cash flow generation requiring external financing to sustain operations. The critical near-term monitoring points include quarterly progress toward operating profit breakeven, success in stabilizing or reducing the 5.1B yen SG&A run-rate, refinancing or extension of the 3.3B yen short-term borrowing concentration, and potential capital raising initiatives to restore equity cushion and address the 0.7% equity ratio.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.